(Total Views: 282)
Posted On: 01/07/2017 1:17:22 PM
Post# of 72447
When you invested in a pre-clinical biotech ran by a rookie CEO and traded on the Pink six years ago, you should expect many growing pains along the way. Running a clinical trial is not as simple as giving the drug to the patient and see whether it works. The whole process is very complex with many moving parts and uncertainties. Leo had to deal with bureaucracies (FDA and universities), private businesses (CRO, drug manufacturers), SEC filings, investor relations, etc.
Six years later you are still invested, despite all the concerns in your email and management's previous connection to NNVC, I guess Leo must be doing something right.
I know everyone expresses their concerns differently. BioHedge for example, holds more than one million shares by himself. He criticized Leo and the BOD he put together prior to uplist, but in a much different tone.
Six years later you are still invested, despite all the concerns in your email and management's previous connection to NNVC, I guess Leo must be doing something right.
I know everyone expresses their concerns differently. BioHedge for example, holds more than one million shares by himself. He criticized Leo and the BOD he put together prior to uplist, but in a much different tone.
Quote:
I've already been invested for 5-6 years.
(0)
(0)
